25D-NBOMe (or NBOMe-2C-D) is a derivative of the
phenethylamine derived hallucinogen
2C-D. It acts in a similar manner to related compounds such as
25I-NBOMe, which is a potent
agonist at the
5-HT2Areceptor.[2][3] 25D-NBOMe has been sold as a street drug since 2010 and produces similar effects in humans to related compounds such as
25I-NBOMe and
25C-NBOMe.[4] It was banned as a
Temporary Class Drug in the UK on 10 June 2013 after concerns about its recreational use.[5]
NBOMe and NBOHs are regularly sold as LSD in blotter papers,[7][15] which have a bitter taste and different safety profiles.[9][6] Despite high potency, recreational doses of LSD have only produced low incidents of acute toxicity.[6] Fatalities involved in NBOMe intoxication suggest that a significant number of individuals ingested the substance which they believed was LSD,[11] and researchers report that "users familiar with LSD may have a false sense of security when ingesting NBOMe inadvertently".[9] While most fatalities are due to the physical effects of the drug, there have also been reports of death due to
self-harm and suicide under the influence of the substance.[16][17][9]
Given limited documentation of NBOMe consumption, the long-term effects of the substance remain unknown.[9] NBOMe compounds are not active orally,[a] and are usually taken sublingually.[19]: 3 When NBOMes are administered sublingually,
numbness of the tongue and mouth followed by a metallic chemical taste was observed, and researchers describe this physical side effect as one of the main discriminants between NBOMe compounds and LSD.[20][21][22]
Many of the NBOMe compounds have high potency agonist activity at additional 5-HT receptors and prolonged activation of 5-HT2B can cause cardiac valvulopathy in high doses and chronic use.[7][12] 5-HT2B receptors have been strongly implicated in causing drug-induced
valvular heart disease.[23][24][25] The high affinity of NBOMe compounds for
adrenergic α1 receptor has been reported to contribute to the stimulant-type cardiovascular effects.[12]
In vitro studies, 25C-NBOMe has been shown to exhibit
cytotoxicity on neuronal cell lines
SH-SY5Y,
PC12, and SN471, and the compound was more potent than
methamphetamine at reducing the visibility of the respective cells; the neurotoxicity of the compound involves activation of
MAPK/ERK cascade and inhibition of
Akt/PKB signaling pathway.[8] 25C-NBOMe, including the other derivative 25D-NBOMe, reduced the visibility of
cardiomyocytes H9c2 cells, and both substances downregulated expression level of p21 (CDC24/RAC)-activated kinase 1 (PAK1), an enzyme with documented cardiac protective effects.[8]
Preliminary studies on 25C-NBOMe have shown that the substance is toxic to development, heart health, and brain health in
zebrafish, rats, and Artemia salina, a common organism for studying potential drug effects on humans, but more research is needed on the topic, the dosages, and if the toxicology results apply to humans. Researchers of the study also recommended further investigation of the drug's potential in damaging pregnant women and their fetus due to the substance's damaging effects to development.[26][27]
As of October 2015 25D-NBOMe is a controlled substance in China.[28]
Sweden
Sveriges riksdag added 25D-NBOMe to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of Aug 1, 2013, published by
Medical Products Agency in their regulation LVFS 2013:15 listed as 25D-NBOMe 2-(2,5-dimetoxi-4-metylfenyl)-N-(2-metoxibensyl)etanamin.[29]
Unregulated at a federal and state level, though arguably may contravene the
Federal Analog Act under certain circumstances given its structural and functional similarity to controlled substance 2C-D.
^The
potency of N-benzylphenethylamines via buccal, sublingual, or nasal absorption is 50-100 greater (by weight) than oral route compared to the parent
2C-x compounds.[18] Researchers hypothesize the low oral metabolic stability of N-benzylphenethylamines is likely causing the low bioavailability on the oral route, although the metabolic profile of this compounds remains unpredictable; therefore researchers state that the fatalities linked to these substances may partly be explained by differences in the metabolism between individuals.[18]
^Hansen M (2010-12-16). Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain (Ph.D. thesis). University of Copenhagen.
doi:
10.13140/RG.2.2.33671.14245.
^"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from
the original on 1 October 2015. Retrieved 1 October 2015.